Japan Pharmaceutical Information

Japan Pharmaceutical Information

Japan Pharmaceutical Information

• February 19, 2016
• Read time: 1 minute

On February 12, Japan's Ministry of Health, Labour and Welfare published an announcement that a Pharmaceutical Affairs and Food Sanitation Council Medical Drug Review Meeting Part 2 is scheduled for February 26. The agenda includes:

• LDK378 (Non-Small Cell Lung Cancer)

• AZD9291 (Non-Small Cell Lung Cancer)

• Radium 223 (Prostate Cancer)

• Ibrutinib (Leukemia)

Ministry of Health, Labour and Welfare webpage:

http://www.mhlw.go.jp/stf/shingi2/0000112329.html

【Important Note】Medical Supporter translates clinical trial data and pharmaceutical information from overseas. This is not intended to encourage participation in clinical trials or use of new drugs. If there are links published by clinical trial units, you can contact them directly. If you're unclear how to reach out, please contact us.

#Lung Cancer #Prostate Cancer #Leukemia

• Clinical Trial Medications

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase II Clinical Trial Results. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer
• Prostate cancer